Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR4 | O00206 | 1/20 | 0.46 |
| ▸ | TLR2 | O60603 | 1/20 | 0.46 |
| ▸ | PARP10 | Q53GL7 | 3/20 | 0.46 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.46 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.45 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | PARP15 | Q460N3 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2202527 | 1.00 | TLR4 (0.46) | TLR4TLR2PARP10SLC2A1SIRT2 | |
| SCHEMBL2204247 | 1.00 | TLR4 (0.46) | TLR4TLR2PARP10SLC2A1SIRT2 | |
| SCHEMBL30580721 | 1.00 | TLR4 (0.46) | TLR4TLR2PARP10SLC2A1SIRT2 | |
| SCHEMBL2207362 | 0.99 | SLC2A1 (0.44) | TLR4TLR2PARP10SLC2A1SIRT2 | |
| SCHEMBL2206503 | 0.96 | TLR4 (0.45) | TLR4TLR2PARP10SLC2A1SIRT2 | |
| SCHEMBL2204225 | 0.96 | PARP10 (0.45) | TLR4TLR2PARP10SLC2A1PARP15 | |
| SCHEMBL2206248 | 0.93 | TAAR1 (0.45) | TLR4TLR2 | |
| SCHEMBL13881548 | 0.92 | TAAR1 (0.51) | TLR4TLR2PARP10SLC2A1SIRT2 | |
| SCHEMBL31220912 | 0.92 | TAAR1 (0.51) | TLR4TLR2PARP10SLC2A1SIRT2 | |
| SCHEMBL21100026 | 0.90 | SPHK2 (0.44) | TLR4TLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12029708-B2 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2024-07-09 | — | — | US | disclosed |
| US-12029708-B2 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2024-07-09 | — | — | US | disclosed |
| US-12029708-B2 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2024-07-09 | — | — | US | disclosed |
| US-11771664-B2 | Toxic aldehyde related diseases and treatment | ALDEYRA THERAPEUTICS, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-11701331-B2 | Toxic aldehyde related diseases and treatment | ALDEYRA THERAPEUTICS, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| US-20230218549-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ACUCELA INC. | 2023-07-13 | — | — | US | disclosed |
| US-20230218549-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ACUCELA INC. | 2023-07-13 | — | — | US | disclosed |
| US-20230218549-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ACUCELA INC. | 2023-07-13 | — | — | US | disclosed |
| US-11446261-B2 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2022-09-20 | — | — | US | disclosed |
| US-20220202745-A1 | TOXIC ALDEHYDE RELATED DISEASES AND TREATMENT | ALDEYRA THERAPEUTICS, INC. | 2022-06-30 | — | — | US | disclosed |
| US-7982071-B2 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2011-07-19 | — | — | US | disclosed |
| US-7982071-B2 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2011-07-19 | — | — | US | disclosed |
| US-7982071-B2 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2011-07-19 | — | — | US | disclosed |
| WO-2011003103-A2 | PHARMACOLOGY OF VISUAL CYCLE MODULATORS | ACUCELA, INC. (US) | 2011-01-06 | — | — | WO | disclosed |
| US-20090326074-A1 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2009-12-31 | — | — | US | disclosed |
| US-20090326074-A1 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2009-12-31 | — | — | US | disclosed |
| US-20090326074-A1 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2009-12-31 | — | — | US | disclosed |
| EP-2091955-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | Acucela, Inc. (US) | 2009-08-26 | — | — | EP | disclosed |
| WO-2009045479-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ACUCELA INC. (US) | 2009-04-09 | — | — | WO | disclosed |
| WO-2009045479-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ACUCELA INC. (US) | 2009-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12029708-B2 | Alkoxy compounds for disease treatment | ALDH1A2, CLN6, AGER | TLR4 595/4885TLR2 943/4885PARP10 1814/4885 |
| US-20230218549-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ALDH1A2, CLN6, AGER | TLR4 517/4885TLR2 890/4885PARP10 1846/4885 |
| US-11771664-B2 | Toxic aldehyde related diseases and treatment | ALDH1A2, ALDH2, ALDH1A1 | TLR4 204/4885TLR2 277/4885PARP10 670/4885 |
| US-11701331-B2 | Toxic aldehyde related diseases and treatment | ALDH1A2, ALDH2, ALDH1A1 | TLR4 204/4885TLR2 277/4885PARP10 670/4885 |
| US-11446261-B2 | Alkoxy compounds for disease treatment | ALDH1A2, CLN6, AGER | TLR4 595/4885TLR2 943/4885PARP10 1814/4885 |
| US-20220202745-A1 | TOXIC ALDEHYDE RELATED DISEASES AND TREATMENT | ALDH1A2, ALDH2, ALDH1A1 | TLR4 204/4885TLR2 277/4885PARP10 670/4885 |
| US-20090326074-A1 | Alkoxy compounds for disease treatment | ALDH1A2, CLN6, AGER | TLR4 595/4885TLR2 943/4885PARP10 1814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.